Vaccine. 2004 Aug 13;22(23-24):3080-6.

A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers.

Leroux-Roels G, Depla E, Hulstaert F, Tobback L, Dincq S, Desmet J, Desombere I, Maertens G.

Source

Center for Vaccinology, Ghent University and Hospital, De Pintelaan 185, B-9000 Ghent, Belgium.

Abstract

The tolerability and immunogenicity of the hepatitis C virus E1 protein as a candidate vaccine was examined in a Phase I, single-arm study. Twenty healthy male volunteers were injected in the deltoid muscle at weeks 0, 3 and 6 with 20 microg recombinant E1 adsorbed on alum. A fourth (booster) dose was administered to 19 subjects at week 26. The candidate therapeutic vaccine was well tolerated. Three vaccine doses induced a clear humoral anti-E1 response that was boosted by a fourth dose. A strong, specific cellular immune response towards E1 was elicited in all vaccine recipients, which included a clear Th1 type response in all but one of the subjects.

PMID:: 15297058; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

COS Scholar Universe

Medical

Hepatitis C - MedlinePlus Health Information

Supplemental Content

Related citations

Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection. [Hum Vaccin. 2005]
Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection.
Leroux-Roels G, Batens AH, Desombere I, Van Den Steen B, Vander Stichele C, Maertens G, Hulstaert F. Hum Vaccin. 2005 Mar-Apr; 1(2):61-5. Epub 2005 Mar 21.
Co-expressing GP5 and M proteins under different promoters in recombinant modified vaccinia virus ankara (rMVA)-based vaccine vector enhanced the humoral and cellular immune responses of porcine reproductive and respiratory syndrome virus (PRRSV). [Virus Genes. 2007]
Co-expressing GP5 and M proteins under different promoters in recombinant modified vaccinia virus ankara (rMVA)-based vaccine vector enhanced the humoral and cellular immune responses of porcine reproductive and respiratory syndrome virus (PRRSV).
Zheng Q, Chen D, Li P, Bi Z, Cao R, Zhou B, Chen P. Virus Genes. 2007 Dec; 35(3):585-95. Epub 2007 Oct 6.
Deletion of N-glycosylation sites of hepatitis C virus envelope protein E1 enhances specific cellular and humoral immune responses. [Vaccine. 2007]
Deletion of N-glycosylation sites of hepatitis C virus envelope protein E1 enhances specific cellular and humoral immune responses.
Liu M, Chen H, Luo F, Li P, Pan Q, Xia B, Qi Z, Ho WZ, Zhang XL. Vaccine. 2007 Sep 4; 25(36):6572-80. Epub 2007 Jul 23.
Review Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics. [Gastroenterology. 2003]
Review Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics.
Kaplan M, Gawrieh S, Cotler SJ, Jensen DM. Gastroenterology. 2003 Aug; 125(2):597-604.
Review Prospects for prophylactic and therapeutic hepatitis C virus vaccines. [Princess Takamatsu Symp. 1995]
Review Prospects for prophylactic and therapeutic hepatitis C virus vaccines.
Houghton M, Choo QL, Kuo G, Weiner A, Chien D, Ralston R, Urdea M, Moss B, Purcell R, Cummins L. Princess Takamatsu Symp. 1995; 25:237-43.

See reviews... See all...

Cited by 7 PubMed Central articles

Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives. [Viruses. 2009]
Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives.
Major ME. Viruses. 2009 Sep; 1(2):144-65. Epub 2009 Aug 12.
Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. [J Infect Dis. 2011]
Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies.
Verstrepen BE, Depla E, Rollier CS, Mares G, Drexhage JA, Priem S, Verschoor EJ, Koopman G, Granier C, Dreux M, et al. J Infect Dis. 2011 Sep 15; 204(6):837-44.
Review Vaccination for hepatitis C virus: closing in on an evasive target. [Expert Rev Vaccines. 2011]
Review Vaccination for hepatitis C virus: closing in on an evasive target.
Halliday J, Klenerman P, Barnes E. Expert Rev Vaccines. 2011 May; 10(5):659-72.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

A candidate vaccine based on the hepatitis C E1 protein: tolerability and immuno...
A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers.
Vaccine. 2004 Aug 13 ;22(23-24):3080-6.

PubMed
Early events of electroporation-mediated intramuscular DNA vaccination potentiat...
Early events of electroporation-mediated intramuscular DNA vaccination potentiate Th1-directed immune responses.
J Gene Med. 2005 Sep ;7(9):1246-54.

PubMed
A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients...
A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C.
Hepatology. 2003 Nov ;38(5):1289-96.

PubMed
Consensus proposals for a unified system of nomenclature of hepatitis C virus ge...
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.
Hepatology. 2005 Oct ;42(4):962-73.

PubMed
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the pe...
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.
Gastroenterology. 2008 May ;134(5):1385-95. Epub 2008 Mar 4 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Related citations

Cited by 7 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information